Basel Long COVID-19 Cohort Study

Study Overview
=================
Brief Summary
-----------------
The Basel Long COVID Cohort Study (BALCoS) will focus on the patients' present health status, symptoms, the course of these symptoms, and potential mechanisms involved. The project aims to investigate proposed mechanisms behind Post COVID-19 condition (PCC), including a) autoimmunity, b) chronic inflammation, c) genetics, d) coagulation disorders, and e) psychosocial factors. Patients enrolled in BALCoS will complete a set of assessments that include the collection of sociodemographic and clinical data, biomarkers, neurocognitive testing, psychometric questionnaires, and measures of physical performance, and provide consent that their data from routine clinical care can be used for the study. As in this registry-based cohort study no intervention besides standard care including individual remedies is given to patients.

Official Title
-----------------
BALCoS - Basel Long COVID Cohort Study

Conditions
-----------------
Post COVID-19 Condition (PCC)

Intervention / Treatment
-----------------
* Other: Data collection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients diagnosed with PCC will be included. PCC will be defined as: History of confirmed or suspected SARS CoV-2 infection Symptoms usually start within 3 months from the onset of acute SARS CoV-2 infection with symptoms and effects that last for at least 2 months Symptoms cannot be explained by an alternative diagnosis signed informed consent is required Exclusion Criteria: Age <18 years Lack of consent to participate in the study Language barriers (lack of sufficient knowledge of German) Lack of general understanding of study procedures

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Data collection|Data collection on sociodemography, clinical data (retrieved from regular care for PCC in the UHB medical outpatient clinic), biomarkers derived from blood samples, neurocognitive testing, psychometric questionnaires, and measures of physical performance.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in World Health Organization Disability Assessment Schedule (WHODAS 2.0) (12- item version) | The World Health Organization Disability Assessment Schedule (WHODAS 2.0) assesses and classifies disability due to health problems during the past 4 weeks. This study will utilize the 12- item version. Items are answered on a 5-point scale ranging from 0 = none to 4 = extreme or cannot do. | At Baseline, T1 (BL + 3 months), T2 (BL + 6 months); T3 (BL + 12 months) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
fatigue, Coronavirus disease (COVID), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Somatic Symptom Disorder (SSD), shortness of breath, cognitive dysfunction